4E THERAPEUTICS, INC.
Optimized MNK kinase inhibitor molecule for neuropathic pain treatment with restricted CNS penetration
- Sector
- Biotech
- Headquarters
- Austin, TX
- Founded
- 2019
- Latest Form D
- $1.9M, Nov 2021
- Total capital
- $7.5M
- Federal grants
- $5.6M
- 1 award · 2021
- Rank in peer group#132 of 514
- Private capital raised
- $1.9M
- 1 Form D · last Nov 2021
- 59 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 23 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$1.9M
- Federal grantHealth and Human S · Phase II · Development and Optimization of MNK Inhibitors for the Treatment of Neuropathic Pain$5.6M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
2months
from 4E THERAPEUTICS, INC.’s first federal award to its first private round.
- First federal award · Sep 2021
- Health and Human S · $5.6M
- First Form D · Nov 2021
- $1.9M · 1st Form D
- Awards before first raise
- 1 award
An association in public records, not a cause or a prediction.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#132 · top 26%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Eric Craig PriceDirectorNamed in SEC Form D filings
- Joseph Craig PriceDirectorNamed in SEC Form D filings
- Theodore Craig PriceDirectorNamed in SEC Form D filings
- Thomas Craig BensonExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 23- PendingSpirocyclic PYRIDINE-1,5-DIONES Exhibiting Mnk Inhibition And Their Method Of UseUSPTOApplication 18574948
- PendingPYRIDINE-1,5-DIONES Exhibiting Mnk Inhibition And Their Method Of UseUSPTOApplication 18003829
- PendingSolid Dispersion Formulations Of Mnk InhibitorsUSPTOApplication PCTUS2025035260
Show all 23 patent records
- Spirocyclic PYRIDINE-1,5-DIONES Exhibiting Mnk Inhibition And Their Method Of UseJun 12, 2025 · Application 18574948Pending
- PYRIDINE-1,5-DIONES Exhibiting Mnk Inhibition And Their Method Of UseSep 14, 2023 · Application 18003829Pending
- Solid Dispersion Formulations Of Mnk InhibitorsApplication PCTUS2025035260Pending
- Deuterated Mnk InhibitorsApplication PCTUS2025035247Pending
- IMIDAZO[1,5-A]PYRIDINE-1,5-DIONES As Mnk Inhibitors And DegradersApplication PCTUS2025035262Pending
- Formulations Of Mnk InhibitorsApplication PCTUS2025035206Pending
- Solid Dispersion Formulations Of Mnk InhibitorsApplication 63789820Pending
- Mnk Inhibitors For Treating Rheumatoid ArthritisApplication 63711884Pending
- Mnk Inhibitors For Treating Rheumatoid ArthritisApplication 63669549Pending
- IMIDAZO[1,5-a]PYRIDINE-1,5-DIONES AS MNK INHIBITORS AND DEGRADERSApplication 63664977Pending
- Formulations Of Mnk InhibitorsApplication 63664407Pending
- Solid Dispersion Formulations Of Mnk InhibitorsApplication 63664411Pending
- Deuterated Mnk InhibitorsApplication 63664303Pending
- Composition, Methods And UsesApplication PCTUS2024027158Pending
- Solid State Forms Of Mnk InhibitorsApplication PCTUS2024010110Pending
- Solid State Forms Of Mnk InhibitorsApplication 63478409Pending
- Spirocyclic PYRIDINE-1,5-DIONES Exhibiting Mnk Inhibition And Their Method Of UseApplication PCTUS2022035703Pending
- Methods Of Treating Migraine With Mnk InhibitorsApplication 63229882Pending
- PYRIDINE-1,5-DIONES Exhibitng Mnk Inhibition And Their Method Of UseApplication PCTUS2021039982Pending
- Spirocyclic PYRIDINE-1,5-DIONES Exhibiting Mnk Inhibition And Their Method Of UseApplication 63217264Pending
- Composition, Methods And UsesApplication 19480682Pending
- Mnk Inhibitors For The Treatment Of Neuropathic PainApplication 63046325Pending
- Mnk Inhibitors For Treating Rheumatoid ArthritisApplication PCTUS2025037076Pending
Related companies, and why
- DeuteRx LLCSimilar federal contract value in Biotech · null in contracts
- FGH BIOTECH, INC.Similar federal contract value in Biotech · null in contracts
- RegulonixSimilar federal contract value in Biotech · null in contracts
- Hillhurst Biopharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- Agilvax, Inc.Similar federal contract value in Biotech · null in contracts
- RESOLUTE SCIENCE, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .